Table 5.
Health-utility scores for health states described by different attributes of injection-delivery systems for weekly GLP1 RA therapies in patients with T2DM in UK and Italian TTO evaluations
| Mean utility (SD)a | Mean disutility (SD) | |||||
|---|---|---|---|---|---|---|
| Difference from health state A | Difference from health state G | |||||
| UK (Matza et al)12 | Italy (Matza et al)21 | UK (Matza et al)12 | Italy (Matza et al)21 | UK (Matza et al)12 | Italy (Matza et al)21 | |
| A: Oral treatment only | 0.888 (0.120) | 0.900 (0.097) | – | – | – | – |
| Health states with oral and injectable treatment | ||||||
| B: Reconstitution, waiting, needle handling | 0.858 (0.165) | 0.868 (0.109) | −0.030 (0.073) | −0.032 (0.059) | −0.020 (0.042) | −0.022 (0.052) |
| C: Reconstitution, waiting | 0.863 (0.161) | 0.872 (0.109) | −0.025 (0.066) | −0.027 (0.058) | −0.014 (0.032) | −0.018 (0.052) |
| D: Reconstitution, needle handling | 0.868 (0.159) | 0.879 (0.102) | −0.020 (0.063) | −0.020 (0.040) | −0.010 (0.027) | −0.011 (0.030) |
| E: Reconstitution | 0.874 (0.157) | 0.884 (0.100) | −0.014 (0.058) | −0.015 (0.032) | −0.004 (0.016) | −0.006 (0.021) |
| F: Needle handling | 0.874 (0.156) | 0.884 (0.101) | −0.014 (0.058) | −0.016 (0.033) | −0.004 (0.015) | −0.006 (0.021) |
| G: No inconveniences | 0.878 (0.156) | 0.890 (0.100) | −0.010 (0.056) | −0.009 (0.025) | – | – |
Notes:
a
TTO scores on a scale anchored by 0 = dead and 1 = full health.
Abbreviations: RA, receptor agonist; T2DM, type 2 diabetes mellitus; TTO, time trade-off.